Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
Charikleia Kelaïdi(Hôpital Avicenne), Pierre Fenaux(Saint Louis University Hospital), Lionel Adès(Délégation Paris 7), Stéphane de Botton(Université Paris-Saclay), Sophie Park(Centre Hospitalier Universitaire de Grenoble), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Pascale Lepelley, Aspasia Stamatoullas(European Union), Sabine Bréchignac(Université Sorbonne Paris Nord), Didier Bouscary(Université Paris Cité), Lionel Mannone(Hôpital l'Archet), Stéphane Giraudier(Inserm), L. Aljassem(Les Hôpitaux de Chartres), Sophie Raynaud(Hôpital l'Archet), MT Daniel, Hervé Dombret(University of London Institute in Paris), François Dreyfus(Université Paris-Sud), Françoise Picard(Délégation Paris 5)
Cited by 78
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k